Find Fostamatinib Disodium Hexahydrate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

MARKET PLACE

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1025687-58-4, Fostamatinib disodium, R788 disodium, R788 (fostamatinib) disodium, R 788 sodium, R935788 (fostamatinib disodium, r788)
Molecular Formula
C23H24FN6Na2O9P
Molecular Weight
624.4  g/mol
InChI Key
HSYBQXDGYCYSGA-UHFFFAOYSA-L
FDA UNII
X9417132K8

Fostamatinib Disodium Hexahydrate
Fostamatinib Disodium Anhydrous is the anhydrous form of fostamatinib disodium, an orally available Syk kinase inhibitor with potential anti-inflammatory and immunomodulating activities. Fostamatinib inhibits Syk kinase-mediated IgG Fc gamma receptor signaling, resulting in inhibition of the activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage. Syk kinase, widely expressed in hematopoietic cells, is a nonreceptor tyrosine kinase that is involved in coupling activated immunoreceptors to signal downstream events that mediate diverse cellular responses, including proliferation, differentiation, and phagocytosis.
1 2D Structure

Fostamatinib Disodium Hexahydrate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
disodium;[6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxopyrido[3,2-b][1,4]oxazin-4-yl]methyl phosphate
2.1.2 InChI
InChI=1S/C23H26FN6O9P.2Na/c1-23(2)21(31)30(11-38-40(32,33)34)20-14(39-23)6-7-17(28-20)27-19-13(24)10-25-22(29-19)26-12-8-15(35-3)18(37-5)16(9-12)36-4;;/h6-10H,11H2,1-5H3,(H2,32,33,34)(H2,25,26,27,28,29);;/q;2*+1/p-2
2.1.3 InChI Key
HSYBQXDGYCYSGA-UHFFFAOYSA-L
2.1.4 Canonical SMILES
CC1(C(=O)N(C2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)COP(=O)([O-])[O-])C.[Na+].[Na+]
2.2 Other Identifiers
2.2.1 UNII
X9417132K8
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-3-oxo-2,3-dihydro-4h-pyrido(3,2-b)-1,4-oxazin-4-yl)methyl Disodium Phosphate Hexahydrate

2. 2h-pyrido(3,2-b)-1,4-oxazin-3(4h)-one, 6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)-4-pyrimidinyl)amino)-2,2-dimethyl-4-((phosphonooxy)methyl)-

3. 2h-pyrido(3,2-b)-1,4-oxazin-3(4h)-one, 6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)-4-pyrimidinyl)amino)-2,2-dimethyl-4-((phosphonooxy)methyl)-, Sodium Salt (1:2)

4. Fostamatinib

5. Fostamatinib Disodium

6. Fostamatinib Disodium Hydrate

7. Fostamatinib Disodium Salt Hexahydrate

8. R-788 Free Acid

9. R-788 Sodium

10. R-788 Sodium Anhydrous

11. R-788 Sodium Hydrate

12. R-935788 Free Acid

13. R-935788 Sodium Anhydrous

14. R-935788 Sodium Hydrate

15. R788 Free Acid

16. R788 Sodium

17. R788 Sodium Anhydrous

18. R788 Sodium Hydrate

19. R935788 Free Acid

20. R935788 Sodium Anhydrous

21. R935788 Sodium Hydrate

22. Tavalisse

2.3.2 Depositor-Supplied Synonyms

1. 1025687-58-4

2. Fostamatinib Disodium

3. R788 Disodium

4. R788 (fostamatinib) Disodium

5. R 788 Sodium

6. R935788 (fostamatinib Disodium, R788)

7. R 935788 Sodium

8. Tavalisse

9. Tamatinib Fosdium

10. X9417132k8

11. 2h-pyrido(3,2-b)-1,4-oxazin-3(4h)-one, 6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)-4-pyrimidinyl)amino)-2,2-dimethyl-4-((phosphonooxy)methyl)-, Sodium Salt (1:2)

12. Disodium;[6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxopyrido[3,2-b][1,4]oxazin-4-yl]methyl Phosphate

13. R788(fostamatinib Disodium)

14. Disodium (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2h-pyrido[3,2-b][1,4]oxazin-4(3h)-yl)methyl Dihydrogen Phosphate

15. R-935788

16. Fosd

17. Fostamatinib Sodium

18. Unii-x9417132k8

19. R788(disodium)

20. R788, Fostamatinib

21. R788 Disodium (fostamatinib)

22. R788 Sodium Anhydrous

23. Schembl3657651

24. R-788 Sodium Anhydrous

25. Dtxsid70145275

26. Ex-a2146

27. R935788 (fostamatinib Disodium)

28. R935788 - Fostamatinib Disodium

29. R935788 Sodium Anhydrous

30. R-935788 Sodium Anhydrous

31. Akos026750559

32. Ccg-270264

33. Fostamatinib Disodium Salt [mi]

34. Sb40413

35. R788(disodium); Fostamatinib Disodium

36. Ac-28433

37. As-16263

38. C71107

39. J-000725

40. J-518183

41. Q27293710

42. (6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-3-oxo-2,3-dihydro-4h-pyrido(3,2-b)-1,4-oxazin-4-yl)methyl Disodium Phosphate

43. 6-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,2-dimethyl-4-[(phosphonooxy)methyl]-2h-pyrido[3,2-b]-1,4-oxazi N-3(4h)-one Sodium Salt

44. Disodium,[6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxopyrido[3,2-b][1,4]oxazin-4-yl]methyl Phosphate

2.4 Create Date
2008-10-27
3 Chemical and Physical Properties
Molecular Weight 624.4 g/mol
Molecular Formula C23H24FN6Na2O9P
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count15
Rotatable Bond Count9
Exact Mass624.11218009 g/mol
Monoisotopic Mass624.11218009 g/mol
Topological Polar Surface Area192 Ų
Heavy Atom Count42
Formal Charge0
Complexity893
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count3
4 Drug and Medication Information
4.1 Drug Information
1 of 1  
Drug NameTAVALISSE
Active IngredientFOSTAMATINIB DISODIUM
CompanyRIGEL PHARMS INC (Application Number: N209299)

4.2 Drug Indication

Tavlesse is indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments.


5 Pharmacology and Biochemistry
5.1 ATC Code

B02BX


API SUPPLIERS

read-more
read-more

01

Hetero Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Pharmatech Expo 2025
Not Confirmed
arrow

Hetero Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Pharmatech Expo 2025
Not Confirmed
USDMF arrow-down Click Us! arrow-down
CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

02

Patheon

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Pharmatech Expo 2025
Not Confirmed
arrow

Patheon

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Pharmatech Expo 2025
Not Confirmed
USDMF CEP/COS JDMF arrow-down EU-WC NDC KDMF VMF Others AUDIT
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-more

01

Hetero Labs Ltd

India

USDMF

arrow
Pharma, Lab & Chemical Expo
Not Confirmed

01

Pharma, Lab & Chemical Expo
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2022-03-04

Pay. Date : 2022-01-05

DMF Number : 36629

Submission : 2022-02-04

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

JDMF

read-more
read-more

01

Pharma, Lab & Chemical Expo
Not Confirmed
arrow
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

Fostamatinib Disodium Hexahydrate

Registration Number : 304MF10064

Registrant's Address : St. -Peter-Strasse 25, 4020 Linz / Austria

Initial Date of Registration : 2022-04-06

Latest Date of Registration : 2022-04-06

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Fostamatinib Disodium Manufacturers

A Fostamatinib Disodium manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Fostamatinib Disodium, including repackagers and relabelers. The FDA regulates Fostamatinib Disodium manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Fostamatinib Disodium API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Fostamatinib Disodium Suppliers

A Fostamatinib Disodium supplier is an individual or a company that provides Fostamatinib Disodium active pharmaceutical ingredient (API) or Fostamatinib Disodium finished formulations upon request. The Fostamatinib Disodium suppliers may include Fostamatinib Disodium API manufacturers, exporters, distributors and traders.

click here to find a list of Fostamatinib Disodium suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Fostamatinib Disodium USDMF

A Fostamatinib Disodium DMF (Drug Master File) is a document detailing the whole manufacturing process of Fostamatinib Disodium active pharmaceutical ingredient (API) in detail. Different forms of Fostamatinib Disodium DMFs exist exist since differing nations have different regulations, such as Fostamatinib Disodium USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Fostamatinib Disodium DMF submitted to regulatory agencies in the US is known as a USDMF. Fostamatinib Disodium USDMF includes data on Fostamatinib Disodium's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Fostamatinib Disodium USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Fostamatinib Disodium suppliers with USDMF on PharmaCompass.

Fostamatinib Disodium JDMF

The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

The Fostamatinib Disodium Drug Master File in Japan (Fostamatinib Disodium JDMF) empowers Fostamatinib Disodium API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

PMDA reviews the Fostamatinib Disodium JDMF during the approval evaluation for pharmaceutical products. At the time of Fostamatinib Disodium JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

click here to find a list of Fostamatinib Disodium suppliers with JDMF on PharmaCompass.

Fostamatinib Disodium NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Fostamatinib Disodium as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Fostamatinib Disodium API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Fostamatinib Disodium as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Fostamatinib Disodium and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Fostamatinib Disodium NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Fostamatinib Disodium suppliers with NDC on PharmaCompass.

Fostamatinib Disodium GMP

Fostamatinib Disodium Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Fostamatinib Disodium GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Fostamatinib Disodium GMP manufacturer or Fostamatinib Disodium GMP API supplier for your needs.

Fostamatinib Disodium CoA

A Fostamatinib Disodium CoA (Certificate of Analysis) is a formal document that attests to Fostamatinib Disodium's compliance with Fostamatinib Disodium specifications and serves as a tool for batch-level quality control.

Fostamatinib Disodium CoA mostly includes findings from lab analyses of a specific batch. For each Fostamatinib Disodium CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Fostamatinib Disodium may be tested according to a variety of international standards, such as European Pharmacopoeia (Fostamatinib Disodium EP), Fostamatinib Disodium JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Fostamatinib Disodium USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty